Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal
Deal Worth Up To $2.37bn
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.